Psilocybin Explored as Potential Anorexia Treatment in Clinical Trials

Exploring New Treatments for Anorexia

Researchers are exploring psilocybin, the psychoactive compound found in magic mushrooms, as a potential treatment for anorexia nervosa. This comes as conventional psychiatric treatments, such as cognitive-behavioral therapy and antidepressants, are effective in only about half of patients with the disorder. Anorexia nervosa has the highest mortality rate of any psychiatric disorder, with individuals being 18 times more likely to die by suicide than the general population.

Patient Experience with Psilocybin Trials

One individual, identified as Christina, participated in a clinical trial for psilocybin after struggling with anorexia for six years and finding no lasting relief from other therapies. She reported that the trial significantly improved her condition, stating it "saved my life" and prevented her from being "stuck in a hospital loop." Her experience highlights the severe impact of the disease on daily life and the desperation for effective solutions.

The Research Landscape and Future Outlook

While research into psychedelics for mental health is in its early stages, there is growing momentum. The Trump administration has encouraged U.S. drug regulators to fund studies in this area. Robin Carhart-Harris, Ralph Metzner Distinguished Professor, predicts that the U.S. Food and Drug Administration (FDA) could approve psilocybin for treating depression or eating disorders within five years, potentially marking 2026 as a significant year for psychedelics in medicine.